Shares of Vernalis plc (NASDAQ:VNLPY) have earned a consensus broker rating score of 1.00 (Strong Buy) from the one analysts that cover the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong buy recommendation.

Zacks has also assigned Vernalis plc an industry rank of 99 out of 265 based on the ratings given to its competitors.

Separately, Stifel Nicolaus restated a “buy” rating on shares of Vernalis plc in a research note on Saturday, June 25th.

Shares of Vernalis plc (NASDAQ:VNLPY) remained flat at $1.09 during trading on Wednesday. The stock’s market cap is $286.78 million. Vernalis plc has a 12 month low of $1.09 and a 12 month high of $2.43. The stock’s 50 day moving average is $1.09 and its 200 day moving average is $1.24.

About Vernalis plc

Vernalis plc is a commercial-stage pharmaceutical holding company. The Company is engaged in the research, development and commercialization of pharmaceutical products for a range of medical disorders. The Company has two marketed products: Tuzistra XR in the United States prescription cough cold market, and frovatriptan, an acute treatment for migraine.

5 Day Chart for NASDAQ:VNLPY

Get a free copy of the Zacks research report on Vernalis plc (VNLPY)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Vernalis plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vernalis plc and related companies with's FREE daily email newsletter.